Matthew Genyeh Mei, M.D.
Other Languages Spoken
A graduate of Harvard and Case Western Reserve University, Matthew Mei, M.D. joined City of Hope in 2011 as a hematology/oncology fellow. In 2014 he was named Assistant Clinical Professor in the Department of Hematology and Hematopoietic Cell Transplantation.
Although he's just beginning a promising career, Dr. Mei’s findings have been the subject of numerous presentations and he has already published four papers in peer-reviewed literature.
- 2014-present, Assistant Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation
- 2011-2014, On-call medicine physician, City of Hope, Duarte, CA
- 2010-2011, Oncology hospitalist, University of California, San Francisco, CA
- 2007, M.D., Case Western Reserve University, Cleveland, OH
- 2003, A.B. magna cum laude, biochemical sciences, Harvard University, Cambridge, MA
- 2011-present, Hematology/oncology fellow
- 2007-2010, Internal medicine resident, University of California, San Francisco, CA
- 2009, California Medical License
- 2009 , Drug Enforcement Agency Certificate
- 2010, Board Certification, American Board of Internal Medicine
2013 Mei M, Thomas S, Chen R. Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody-Drug Conjugates: Focus on Brentuximab Vedotin. BioDrugs. 2013 Nov 21. [Epub ahead of print]
2013 Krishnan AY, Mei M, Sun C, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant.2013 Feb;19(2):260-5.
2006 Mei M, Zhu X, Harrison K, Su B, Previll L, Jackson L, Cai DX, Perry G, Zhu X. Distribution, levels, and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem. 2006 Dec;99(5):1377-88.
2005 Zhu X, Mei M, Lee HG, Wang Y, Han J, Perry G, Smith MA. P38 activation mediates amyloid-beta cytotoxicity. Neurochem Res. 2005 Jun-Jul;30(6-7): 791-6.